Maze Therapeutics (MAZE) Cash from Investing Activities (2024 - 2026)

Maze Therapeutics has reported Cash from Investing Activities for 3 years, with the latest figure at $6.3 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 2198.66% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$164.4 million (down 13986.38% YoY) and the FY2025 annual result came in at -$171.0 million, down 14805.14% from the prior year.
• Cash from Investing Activities improved to $6.3 million in Q1 2026 per MAZE's latest filing, from -$103.4 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $6.3 million in Q1 2026 and troughed at -$103.4 million in Q4 2025.
• A 3-year average of -$18.4 million and a median of -$299000.0 in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities tumbled 64834.95% in 2025, then jumped 2198.66% in 2026.
• Over 3 years, Cash from Investing Activities stood at -$605000.0 in 2024, then sank by 16988.76% to -$103.4 million in 2025, then soared by 106.07% to $6.3 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $6.3 million, -$103.4 million, and -$66.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.